NEW YORK and LONDON, March 30th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics Announces FDA Fast Track Designation For Coversin
Akari Therapeutics Announces R&D Day on April 24, 2017
NEW YORK and LONDON, March 17th, 2017 -- Presentation to Include New Coversin Phase II Data in PNH and Latest Data on Pipeline – Akari Therapeutics …
[Read more...] about Akari Therapeutics Announces R&D Day on April 24, 2017
Akari Therapeutics to Present at the 29th Annual ROTH Conference
NEW YORK and LONDON, March 7th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics to Present at the 29th Annual ROTH Conference
Akari Therapeutics to Attend Upcoming Investor Conferences in February
NEW YORK and LONDON, January 31st, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics to Attend Upcoming Investor Conferences in February
Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
NEW YORK and LONDON, January 4th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its …
[Read more...] about Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
